Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Gene editing could pave way for pig organ transplants: U.S. study

Published 10/12/2015, 02:31 PM
Updated 10/12/2015, 02:31 PM
Gene editing could pave way for pig organ transplants: U.S. study

CHICAGO (Reuters) - U.S. researchers have used a new gene editing technique to trim away potentially harmful virus genes that have impeded the use of pig organs for transplants in humans.

The study, published in the journal Science, expands on capabilities of the genome editing tool known as CRISPR–Cas9, which works as a type of molecular scissors that can selectively trim away unwanted parts of the genome.

Previous efforts with the technology have only managed to cut away six areas of the genome at one go. In the latest study led by Dr. George Church, a geneticist from Harvard Medical School, researchers simultaneously snipped away genetic material in 62 specific locations in the pig genome.

While Church's team has shown that it is feasible to drastically edit the genome of pigs to remove native pig viruses from pig cells, it has not shown that such organs would be safe to use in people.

Still, Church said in a statement he believes the technology will one day make it possible for pig organs to be used as a substitute for human organs for patients in need of a transplant and for whom there are no suitable donor organs.

Church first revealed his team's feat at an Oct. 5 workshop at the National Academy of Sciences, which is studying the potential risks and ethical concerns of human genome editing.

The technology has ignited an ethical debate after biologists in China reported carrying out the first experiment to alter the DNA of human embryos. British scientists have subsequently asked for permission to edit human embryos.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In the pig experiment, one concern is the potential for genomic rearrangements, in which the editing technique inadvertently makes unwanted changes to the genome. In the Harvard trial, this did not appear to happen.

Church has co-founded a biotechnology company called eGenesis to produce pigs for organ transplants.

Pig-to-human transplants are not novel. Currently, pig heart valves that have been scrubbed and depleted of pig cells are commonly used to repair faulty human heart valves. But whole pig organs, which are functionally similar to human organs, cannot be used because of the potential for transmission of latent retroviruses, which are harmless in pigs, but could cause illness in people.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.